Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: One-year clinical outcomes (RECONFIRM-2)

Modern Rheumatology

Volumn 18, Issue 2, 2008, Pages 146-152

  Tanaka, Yoshiya ^a   Takeuchi, Tsutomu ^b   Inoue, Eisuke ^c   Saito, Kazuyoshi ^a   Sekiguchi, Naoya ^b   Sato, Eri ^c   Nawata, Masao ^a   Kameda, Hideto ^b   Iwata, Shigeru ^a   Amano, Kouichi ^b   Yamanaka, Hisashi ^c  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

EULAR response; Infliximab; Retrospective study; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; FEMALE; HEALTH STATUS; HUMANS; JAPAN; JOINTS; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 41849132452     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0026-3     Document Type: Article

References (16)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356-61.
2. Weaver AL. Efficacy and safety of the anti-TNF biologic agents. Mod Rheumatol. 2004;14:101-12.
3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis. Guidelines for the management of rheumatoid arthritis, 2002 update. Arthritis Rheum 2002;46:328-46.
4. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45.
5. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370(9602):1861-74.
6. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. Lancet. 1999;354:1932-9.
7. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-602.
8. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051-65.
9. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement - a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52:1020-30.
10. Smolen JS, van Der Heijde DM, St Clair EW, et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial. Arthritis Rheum. 2006;54:702-10.
11. Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, Iikuni N, Nawata M, Amano K, Shinozaki M, Takeuchi T. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28-32.
12. Miyasaka N, Takeuchi T, Eguchi K. Offi cial Japanese Guidelines for the use of infl iximab for rheumatoid arthritis. Modern Rheum. 2005;15:4-8.
13. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of DAS28-ESR and DAS28-CRP on threshold values. Ann Rheum Dis. 2007;66:407-9.
14. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Post-marketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008;67(2):189-94.
15. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis. 2005;64:1274-9.
16. Wendling D, Materne GE, Michel F, Lohse A, Lehuede G, Toussirot E, Massol J, Woronoff-Lemsi MC. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine. 2005;72:309-12.